Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
3
users have commented on this narrative
45
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Broadwind
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Policy Shifts Will Cripple Wind Orders And Spur Cautious Recovery
Key Takeaways Growth depends heavily on continued policy support for renewables, while future technological shifts and global competition threaten pricing and market relevance. Short-term cost pressures and manufacturing inefficiencies persist, despite investments in automation and process improvements aimed at boosting long-term margins.
View narrative
US$3.00
FV
24.0% undervalued
intrinsic discount
0.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
2 days ago
author updated this narrative
Heritage Global
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Rising Competition And Compliance Will Limit Transactions While Efficiency Advances
Key Takeaways Automation and digital direct transactions could reduce Heritage Global's intermediary role, limiting revenue growth amid rising industry competition and innovation. Compliance costs and limited scale risk eroding margins; weaker brand and declining manufacturing may constrain long-term revenue and profitability opportunities.
View narrative
US$3.00
FV
36.3% undervalued
intrinsic discount
7.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
VirTra
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Government Delays And Tough Competition Will Constrain Then Yield Progress
Key Takeaways Heavy dependence on public funding and slow procurement cycles create ongoing revenue volatility and limit near-term growth visibility. Rising operational costs and competition from lower-cost alternatives jeopardize long-term margins despite strong recurring revenue streams and international expansion opportunities.
View narrative
US$7.00
FV
23.1% undervalued
intrinsic discount
8.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
X4 Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Intensifying Trial Risks Will Hobble Returns Yet Open Global Potential
Key Takeaways Reliance on a single drug and competitive pressures from new therapies create significant risks to X4's future growth, profitability, and market share. Ongoing financial losses, regulatory challenges, and capital constraints threaten shareholder value and may delay the company's expansion into new markets.
View narrative
US$3.50
FV
18.6% undervalued
intrinsic discount
10.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
2 days ago
author updated this narrative
Puma Biotechnology
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Single-Asset Reliance Will Deepen Revenue Erosion
Key Takeaways Heavy dependence on a single aging product leaves Puma vulnerable to generic competition and shifts in physician treatment preferences. Mounting pricing pressures, regulatory costs, and weak pipeline advancement threaten revenue growth and long-term profitability.
View narrative
US$2.00
FV
186.5% overvalued
intrinsic discount
-3.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
DHI Group
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Digital Shifts And Competition Will Undermine Revenues Yet Spark Recovery
Key Takeaways Reliance on specialized tech hiring and government spending exposes DHI to industry volatility, competition, and risks of employers bypassing traditional recruitment platforms. Efforts to diversify offerings and boost operational efficiency may be undermined by DHI's limited brand reach and margin pressures from larger, multi-function hiring platforms.
View narrative
US$3.00
FV
27.0% undervalued
intrinsic discount
-6.24%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Stabilis Solutions
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Multi-year Contract Risks Will Pressure LNG While Optimism Grows
Key Takeaways Stabilis faces risks from regulatory shifts toward renewables and intensifying competition, which could shorten LNG's relevance and lead to revenue volatility and stranded assets. Heavy capital investment and reliance on securing long-term customer commitments may expose the company to delayed returns, margin pressures, and elevated compliance costs.
View narrative
US$9.00
FV
50.3% undervalued
intrinsic discount
12.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Sensus Healthcare
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
US Regulations Will Curtail Sales Yet Unveil Opportunities
Key Takeaways Heavy dependence on a limited product line and U.S. market exposes vulnerability to regulatory, reimbursement, and technological disruptions impacting future growth and margins. Competition from alternative therapies and cost constraints could suppress equipment sales and slow adoption, limiting sustainable revenue and procedure volumes.
View narrative
US$6.00
FV
44.2% undervalued
intrinsic discount
20.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Crexendo
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Tech Competition Will Pressure Revenues But Oracle Cloud Offers Relief
Key Takeaways Intensifying competition and industry consolidation threaten Crexendo's pricing power, market share, and long-term revenue growth prospects. Heavy reliance on SMB customers, innovation pressures, and growing compliance costs introduce significant risks to recurring revenues and net margins.
View narrative
US$7.50
FV
16.4% undervalued
intrinsic discount
12.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Value any company in seconds
Popular companies